Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Healthcare/biotech

Innovent’s license deal

So big but so what? Innovent’s license deal fails to excite investors

The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $11.4 billion, pocketing a big downpayment, so why did its stock price fall?…
October 30, 2025
1801.HK
Eccogene files for Hong Kong IPO

Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO

The Chinese biotech is developing a weight-loss drug in a tablet form that could challenge leading products in the booming anti-obesity market Key Takeaways: The AstraZeneca licensing deal in 2023…
October 23, 2025
InnoCare licensing deal

InnoCare licensing deal flops due to lack of upfront cash

The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
October 16, 2025
9969.HK 688428.SHG
PomDoctor provides online medical care

PomDoctor completes U.S. listing ahead of looming Nasdaq crackdown

The online medical services provider raised about $20 million after pricing its shares at the bottom of their range – below a Nasdaq-proposed new minimum threshold of $25 million Key…
October 10, 2025
POM.US
Obesity drug maker Sciwind IPO

Obesity drug maker Sciwind targets IPO, with heavyweight backers

Supported by Tencent and Meituan, the biotech aims to launch a targeted GLP-1 drug next year that could challenge established products, but it faces stiff competition Key Takeaways: • Clinical…
October 9, 2025
A wild ride for TransThera investors

A wild ride for TransThera investors: what’s the story?

The firm’s core drug has passed a minor clinical milestone, but the rally really took off when the stock was included in an array of indices tracked by passive funds…
September 25, 2025
2617.HK
Work Medical makes medical devices

WORK Medical enters strategic partnerships in bid to explore RWA initiatives

The medical products maker hopes to leverage RWA technology to transform and leverage its current product infrastructure and budding AI business Key Takeaways: WORK Medical has formed a new alliance…
September 24, 2025
WOK.US
Load more

Recent Articles

Hesai and Seyond make LiDAR technology
October 30, 2025

NEWS WRAP: Seyond sued by rival ahead of Hong Kong SPAC listing

October 30, 2025

BRIEF: Shandong Gold’s profit surges 91% in first three quarters

1787.HK 600547.SHG
October 30, 2025

Pet tech boom lifts Dogness revenue, but investors aren’t biting

DOGZ.US
October 30, 2025

NEWS WRAP: Lalatech posts double-digit growth as overseas momentum continues

October 30, 2025

BRIEF: Midea Group posts rising profit and revenue in third quarter

0300.HK 000333.SHE
October 29, 2025

From software to the skies, China’s self-sufficiency drive meets economic reality

3888.HK
October 29, 2025

BRIEF: ZTE profit plunges 87% in third quarter

0763.HK 000063.SHE

RELATED ARTICLES

  1. Klook prepares to list in US
    July 18, 2025
    Klook goes against the flow with U.S. listing plan
  2. June 24, 2025
    Nameson’s profit dives on diversification spending, overreliance on single customer
    1982.HK
  3. July 7, 2025
    Moore Threads taps China IPO investors as it faces challenges, opportunities
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.